History of jaundice or persistent pruritus during a previous pregnancy. History of herpes of pregnancy. Previous or existing liver tumours. Presence or history of meningioma. Wasting diseases. Severe chronic depression. Previous or existing thromboembolic processes. Severe diabetes with vascular changes.
Sickle-cell anaemia. Hypersensitivity to any of the components of Cyprone With regard to the cyclical combined therapy of severe signs of androgenisation, attention is also drawn to the data on contraindications contained in the product information for the progestogen-oestrogen containing preparation used in addition to Cyprone Contraindications in men.
Inoperable carcinoma of the prostate. Previous or existing liver tumours only if these are not due to metastases from carcinoma of the prostate. Wasting diseases with the exception of inoperable carcinoma of the prostate. Existing thromboembolic processes.
Cyprone 50 should not be given before the conclusion of puberty, since an unfavourable influence on longitudinal growth and the still unstabilised axes of endocrine function cannot be ruled out. During treatment liver function, adrenocortical function and red blood cell count should be checked regularly. The long term effects on female fertility are not known with certainty. In men of procreative age, for whom fertility could be important after conclusion of the medication, it is advisable to make at least one control spermatogram as a precaution before the start of treatment in order to counter any unjustified claims of later infertility as a result of the antiandrogen therapy.
Spermatogenesis has taken months to return to normal after discontinuing therapy. As with other antiandrogenic treatments, in male patients long-term androgen deprivation with Cyprone 50 may lead to osteoporosis.
Direct hepatic toxicity, including jaundice, hepatitis and hepatic failure, has been observed in patients treated with cyproterone acetate. At dosages of mg and above, cases with fatal outcome have been reported. Most reported fatal cases were in men with advanced carcinoma of the prostate. If hepatotoxicity is confirmed, cyproterone should normally be withdrawn, unless hepatotoxicity can be explained by another cause e. The risk of meningioma increases with increasing cumulative doses of cyproterone acetate.
If a patient treated with Cyprone 50 is diagnosed with meningioma, treatment with cyproterone containing products, including Cyprone 50 must be permanently stopped see Section 4. Strict medical supervision is necessary if the patient suffers from diabetes because the requirement for oral antidiabetics or insulin can change during Cyprone 50 treatment see Section 4.
Shortness of breath. The differential diagnosis in such cases must include the stimulating effect on breathing known for progesterone and synthetic progestogens which is accompanied by hypocapnia and compensated respiratory alkalosis and which is not considered to require treatment.
Thromboembolic events. The occurrence of thromboembolic events has been reported in patients using Cyprone although a causal relationship has not been established. Adrenocortical function. During treatment adrenocortical function should be checked regularly, as preclinical data suggest a possible suppression due to the corticoid-like effect of Cyprone 50 with high doses.
Anaemia has been reported during treatment with cyproterone acetate. Therefore, the red-blood cell count should be checked regularly during treatment. Other conditions. Cyprone 50 tablets contain lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose mal absorption should not take this medicine.
Specifically to be observed in women. Before the start of therapy a thorough general medical and gynaecological examination including the breasts and a cytological smear of the cervix should be carried out. Serious organic causes of androgenisation, e. Cushing's syndrome, ovarian tumours, adrenal carcinoma and adrenogenital syndrome should be excluded. Pregnancy must be excluded at the time of commencing treatment in women of child-bearing potential. If, during the combined treatment, spotting occurs during the 3 weeks in which the tablets are being taken, tablet-taking should not be interrupted.
However, if persistent or recurrent bleeding occurs at irregular intervals, a gynaecological examination must be carried out to exclude organic diseases. With regard to the additional use of a combined oral contraceptive preparation, attention is drawn to all the data contained in the product information for this product.
Specifically to be observed in men. The sexual drive-reducing effect of Cyprone 50 can be diminished under the influence of alcohol. In patients with inoperable carcinoma of the prostate presenting with a history of thromboembolic processes or suffering from sickle-cell anaemia or from severe diabetes with vascular changes, a careful risk: benefit evaluation must be carried out in each individual case before Cyprone 50 is prescribed. See Section 4. Effects on laboratory tests.
No data available. The requirement for oral antidiabetics or insulin can change. Although clinical interaction studies have not been performed, since this drug is metabolized by CYP3A4, it is expected that ketoconazole, itraconazole, clotrimazole, ritonavir and other strong inhibitors of CYP3A4 inhibit the metabolism of cyproterone acetate. On the other hand, inducers of CYP3A4 such as e. John's wort may reduce the levels of cyproterone acetate. The risk of statin-associated myopathy or rhabdomyolysis may be increased when those HMG-CoA inhibitors statins , which are primarily metabolised by CYP3A4, are co-administered with high therapeutic cyproterone acetate doses since they share the same metabolic pathway.
Effects on fertility. Category D The use of Cyprone 50 is contraindicated during pregnancy see Section 4. Administration of cyproterone acetate during the hormone-sensitive differentiation phase of the genital organs after approx. The use of Cyprone 50 is contraindicated during lactation as small amounts of cyproterone acetate are excreted in breast milk see Section 4. It should be pointed out to patients whose occupation demands great concentration e. Adverse reactions reported in clinical trials.
Very common: tiredness, weight increase. Common: headache, depressive moods. Common: thrombotic phenomena. Common: nausea and other gastrointestinal complaints. Very common: diminished libido. Common: mastodynia, irregular menstrual cycles. Rare: rash.
The most commonly reported adverse drug reactions ADRs in female patients receiving cyproterone acetate are spotting, weight increase and depressed mood. The most frequently observed ADRs in male patients receiving cyproterone acetate are decreased libido, erectile dysfunction and reversible inhibition of spermatogenesis. The most serious ADRs in patients receiving cyproterone acetate are hepatic toxicity, benign and malignant liver tumours which may lead to intra-abdominal haemorrhage, and thromboembolic events.
Over the course of several weeks cyproterone acetate gradually impairs spermatogenesis as a result of the antiandrogenic and antigonadotropic actions. Spermatogenesis recovers gradually within several months of discontinuing therapy. In male patients cyproterone acetate occasionally leads to gynaecomastia sometimes combined with tenderness to touch of the breast which usually regresses after discontinuation of treatment or reduction of the dose. As with other antiandrogenic treatments, in male patients long-term androgen deprivation with cyproterone acetate may lead to osteoporosis.
In women ovulation is inhibited under the combined treatment so that a state of infertility exists. A feeling of tension in the breasts may occur. In individual cases, disturbances of liver function, some of them severe, have been reported with high-dosed cyproterone acetate treatment. Changes in body weight are possible. Other adverse events reported at a low incidence were dysmenorrhoea, vaginal discharge, skin discolouration, striae. Post-marketing information.
The following adverse effects have been reported in users of cyproterone acetate. The most appropriate MedDRA term to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well. See Table 1. A causal relationship with Cyprone 50 has not been established. In male patients under treatment with Cyprone 50, sexual drive and potency are reduced and gonadal function is inhibited.
These changes are reversible after discontinuation of therapy. Meningiomas have been reported in association with long-term use several years of Cyprone 50 doses of 25 mg and above see Section 4. Reporting suspected adverse effects. Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions at www. There is no clinical experience in overdose. Assessment and symptomatic treatment should be initiated as required. For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 Australia. Mechanism of action.
Cyprone 50 is an antiandrogenic hormone preparation. Cyproterone acetate inhibits the effect of androgens at androgen dependent target organs, e. Prostatic carcinoma and its metastases are in general androgen-dependent, Cyprone 50 therefore exerts a direct antiandrogenic action on the tumour and its metastases. Cyproterone acetate in addition has a progestogenic action exerting a negative feedback effect centrally on the hypothalamic receptors, so leading to a reduction in gonadotropin release, and hence to diminished production of testicular androgens.
Treatment with cyproterone acetate in men results in a reduction of sexual drive and potency and inhibition of gonadal function. These changes are reversible following discontinuation of the therapy. The antigonadotropic effect of cyproterone acetate is also exerted when the substance is combined with LHRH agonists. The initial increase of testosterone provoked by this substance group is decreased by cyproterone acetate.
During the treatment ovarian function is inhibited. Prolactin levels can increase slightly under higher doses of cyproterone acetate. There are no data for periods longer than 6 months. Clinical trials. Following oral administration, cyproterone acetate is completely absorbed over a wide dose range. Thereafter, drug serum levels declined during a time interval of typically 24 to hours, with a terminal half-life of The total clearance of cyproterone acetate from serum was determined to be 3.
The absolute bioavailability of cyproterone acetate is unknown. The major part of circulating cyproterone acetate is bound to serum albumin. In a study in 15 women receiving 2 mg cyproterone acetate in combination with 35 microgram ethinylestradiol, the free fraction of cyproterone acetate was about 3. Because protein binding is non-specific, changes in SHBG sex hormone binding globulin levels do not affect the pharmacokinetics of cyproterone acetate.
Cyproterone acetate is metabolised by various pathways, including hydroxylations and conjugations. Some dose parts are excreted unchanged with bile fluid. The renal and biliary excretion was determined to proceed with a half-life of 1. Metabolites from plasma were eliminated at a similar rate half-life of 1. Steady state conditions. According to the long half-life of the terminal disposition phase from plasma serum and the daily intake, an accumulation of cyproterone acetate by a factor of about 3 can be expected in the serum during repeated daily administration.
Cyproterone acetate was negative in a standard battery of genotoxicity studies. In vivo consequence of cyproterone acetate treatment were the increased incidence of focal, possibly pre-neoplastic, liver lesions in which cellular enzymes were altered in female rats and an increase of mutation frequency in transgenic rats carrying a bacterial gene as target for mutation. The clinical relevance of these findings presently uncertain.
Because of shortcomings in these studies inadequate pharmacokinetic data and the need to reassess the liver pathology , the carcinogenic potential of cyproterone acetate in animals could not be determined. Clinical experience and limited epidemiological data available to date do not appear to have supported an increased incidence of hepatic tumours in humans. However, it must be borne in mind that steroidal sex hormones can promote the growth of certain hormone-dependent tissues and tumours.
Cyprone 50 contains the following excipients: lactose monohydrate, maize starch, povidone, magnesium stearate, colloidal anhydrous silica and pregelatinised maize starch. Incompatibilities were either not assessed or not identified as part of the registration of this medicine. The expiry date can be found on the packaging. Pack sizes: Each pack contains 20 or 50 tablets.
Some pack sizes may not be marketed. In Australia, any unused medicine or waste material should be disposed of by taking it to your local pharmacy. Chemical structure. Molecular weight: CAS number. Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition.
Please feel free to tell us why. Consumer medicine information Cyprone 50 Cyproterone acetate. See related product images. Consumer medicine information CMI leaflet Please read this leaflet carefully before you start using Cyprone If you have any concerns about taking this medicine, talk to your doctor or pharmacist.
Keep this leaflet with your medicine. You may need to read it again. MEN: In men, androgens may help cancer cells to grow in some types of prostate cancer. Cyprone is also used to reduce abnormal sex drive in men. WOMEN: In women, androgens may increase hair growth, loss of scalp hair and secretion of oil from the sweat glands.
Cyprone 50 is only available on a doctor's prescription. There is no evidence that Cyprone 50 is addictive. Do not take Cyprone if you have any of the following conditions; Liver disease, previous or existing liver tumours unless they are caused by metastases from prostate cancer your doctor would have told you of you have this Dubin-Johnson or Rotor syndrome your doctor would have told you if you have either of these conditions History of jaundice yellow skin or eyes , herpes or persistent itching during a previous pregnancy previous or existing benign brain tumour meningioma wasting disease a disease causing muscle loss or loss of strength, with the exception of prostate cancer severe and persistent depression previous or existing conditions relating to formation of blood clots severe diabetes with blood vessel changes your doctor would have told you if you have this sickle-cell anaemia your doctor would have told you if you have this Cyprone tablets contain lactose monohydrate.
Do not give this medicine to children. If you are not sure whether you should start taking this medicine, talk to your doctor. Before you start to take it Tell your doctor if you have allergies to any other medicines, foods, preservatives or dyes.
Tell your doctor if you have or have had any medical conditions, especially the following: diabetes history of blood clotting or sickle cell anaemia osteoporosis, a family history of osteoporosis or risk factors for developing osteoporosis such as smoking, a diet low in calcium, poor mobility, a slight build or treatment with steroid medicines Tell your doctor if you are pregnant or plan to become pregnant or are breastfeeding. The long-term effects of Cyprone on female fertility are not known.
Taking other medicines Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from a pharmacy, supermarket or health food shop. Some medicines and Cyprone 50 may interfere with each other. These include: phenytoin, a medicine used to treat epilepsy medicines used to treat funal infections, including ketoconazole, itraconazole, clotrimazole ritonavir, a medicine used in the treatment of HIV rifampicin, an antibiotic used to treat infections such as tuberculosis and leprosy St John's wort, a herbal remedy used to treat mood disorders Statins HMGCoA inhibitors , medicines used to lower cholesterol levels in people with or at risk of cardiovascular disease Medicines to treat diabetes These medicines may be affected by Cyprone 50 or may affect how well it works.
How much to take The dosage of Cyprone 50 will be determined by your doctor. Shortness of breath may occur at high doses. How to take it Swallow the tablets whole with some liquid after meals. When to take it Take your medicine after meals at about the same time each day. How long to take it Continue taking your medicine for as long as your doctor tells you. If you forget to take it If it is almost time to take your next dose, skip the dose that you have missed and take your next dose when you are meant to.
Otherwise take it as soon as you remember, then go back to taking your tablets as usual. If you are not sure what to do, ask your doctor or pharmacist. If you take too much overdose Immediately telephone your doctor or the Poisons Information Centre telephone 13 11 26 for advice, or go to Accident and Emergency at the nearest hospital, if you think that you or anyone else may have taken too many Cyprone 50 tablets.
You may be required to have regular tests for liver, blood or other body functions. If you become pregnant while taking this medicine, tell your doctor immediately. Keep all of your doctor's appointments so that your progress can be checked. Things you must not do Do not take Cyprone 50 to treat any other complaints unless your doctor tells you to.
Do not give your medicine to anyone else, even if they have the same condition as you. Things to be careful of Cyprone 50 may cause drowsiness and loss of concentration in some people. Be careful driving or operating machinery until you know how Cyprone 50 affects you. Ask your doctor or pharmacist to answer any questions you may have.
The above includes the more common side effects of your medicine Tell your doctor or pharmacist if you notice anything that is making you feel unwell. Do not use cyproheptadine in larger or smaller amounts or for longer than recommended. Do not give this medicine to a child younger than 2 years old. You should not use antihistamine medication to make a child sleepy. Death can occur from the misuse of an antihistamine in very young children. Measure liquid medicine with the dosing syringe provided, or with a special dose-measuring spoon or medicine cup.
If you do not have a dose-measuring device, ask your pharmacist for one. Tell your doctor if you have any changes in weight. Cyproheptadine doses are based on weight especially in children and teenagers , and any changes may affect the dose. This medicine can cause you to have a false positive drug screening test. If you provide a urine sample for drug screening, tell the laboratory staff that you are taking cyproheptadine.
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose. Overdose symptoms may include extreme drowsiness, hallucinations, very dry mouth, dilated pupils, pale or reddish skin, tingly feeling, vomiting , restlessness in a child , weak or shallow breathing, or a seizure convulsions.
Be careful if you drive or do anything that requires you to be alert. Get emergency medical help if you have signs of an allergic reaction : hives ; difficult breathing; swelling of your face, lips, tongue, or throat. This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
Taking cyproheptadine with other drugs that make you sleepy can worsen this effect. Ask your doctor before taking a sleeping pill, narcotic medication, muscle relaxer, or medicine for anxiety , depression , or seizures.
Other drugs may interact with cyproheptadine, including prescription and over-the-counter medicines, vitamins , and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Treatments Migraine Cyproheptadine Print Save. Detailed Cyproheptadine dosage information.
Furthermore, is highly recommended to apply steroids directly onto the area that needs treating, for instance by inhalation into the lungs for wheezing, as eye drops for eye inflammation, or as an injection directly into an inflamed joint. Some are ingested as pills or injected into muscles or veins. Medical experts are keen on keeping steroid dosages in control; high intake may cause long-term drawbacks.
Some of these are eye cataracts and glaucoma, muscle weakness, high blood pressure, weight gain, inhibited growth in children, thinning of bones, skin problems like bruising or acne, and — worst of all — immune system failure. Antibiotics, on the other hand, are either bactericidal or bacteriostatic in nature.
Bactericidal antibiotics target the bacterial cell wall, membrane, or enzymes. Examples of this are penicillin, cephalosporin, quinolone, and sulfonamide. Bacteriostatic antibiotics are those that directly aim for protein synthesis, such as tetracycline and aminoglycoside. As one may notice, both types directly and specifically target the bacteria. Although antibiotics are prescribed frequently, misuse of these drugs can contribute to the emergence of resistant bacteria that is more difficult, or even impossible, to combat.
It is also likely to have a negative effect on the immune system. For instance, during the bacterial attack, some good bacteria are also killed. The most common of these good guys are responsible for the production of B vitamins and lactase, as well as aiding in fighting tumors, lowering high cholesterol levels, and improving digestion. Without these friendly bacteria, the body is more susceptible to other pathogens that can cause immunological, neurological, or endocrinologic problems.
This overgrowth of pathogens such as yeast Candidiasis has been linked to food allergies, autoimmune disorders, and chemical sensitivities, among others. Cite APA 7 Franscisco,. Difference Between Steroids and Antibiotics. Difference Between Similar Terms and Objects. MLA 8 Franscisco,.
I am allergic to amoxcillin now for swelling due to allergy doctor has prescribed methyprednisolone tablets Medrol. I can take it. Very very helpful. My dog had both dry scabby nose and yellows secretions from it. The first vet gave steroids and yes by next day some scabby and wetness had dried up.
But then he woke up with the yellow secretions from the nose, so I went another vet for a second opinion who prescribed antibiotics. On reading this article it has helped, as initially I will continue with the steroids as it did show some improvement within 12 hours, but shall view his nose secretions and make further decisions later. Of course I will not give both at the same time. Can you tell me if this dual prescribing is a widespread medical trend or just a local one?
Antibiotics are the medicines which we take if we are ill or suffering from any time of disease. We take antibiotics to kill the germs and recovers as soon as possible. Do not use this medication longer than 7 days, unless directed to do so by your doctor. This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
Apply the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not apply extra cream or ointment to make up for a missed dose. Children who use neomycin, polymyxin, bacitracin, and hydrocortisone combination for longer periods of time may have an increased risk of side effects including slowed growth.
Talk to your child's doctor about the risks of applying this medication to your child's skin. Neomycin, polymyxin, bacitracin, and hydrocortisone combination may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture not in the bathroom. It is important to keep all medication out of sight and reach of children as many containers such as weekly pill minders and those for eye drops, creams, patches, and inhalers are not child-resistant and young children can open them easily.
To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location — one that is up and away and out of their sight and reach. Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them.
However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. In case of overdose, call the poison control helpline at If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at It is important for you to keep a written list of all of the prescription and nonprescription over-the-counter medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements.
You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies. Neomycin, Polymyxin, Bacitracin, and Hydrocortisone Topical pronounced as nee" oh mye' sin pol" ee mix' in. Why is this medication prescribed? How should this medicine be used?
What special precautions should I follow? What special dietary instructions should I follow? What should I do if I forget a dose? What side effects can this medication cause? What should I know about storage and disposal of this medication? Brand names Brand names of combination products. Do not wrap or bandage the treated area unless your doctor tells you that you should.
Patients should not take it. Ans: Sleepiness is the most before starting or stopping any. Avoid combinations; the risk of the interaction outweighs the benefit. Always consult your healthcare provider were found for your selected. The relevance of a particular the classification of antihistaminic drugs. Please upgrade your browser or download modern browsers from here. Therapeutic duplication warnings No warnings common side effect of this. PARAGRAPHAlways consult your steroids and glandular fever provider to ensure the information displayed. Ans: Cypon Capsule comes under drug interaction to a specific. Ans: No, this medication is only used to cure allergies.Prednisone · Vicodin · Warfarin · Wellbutrin · Xanax · Zocor · Zoloft. Show More Show Less. Select a condition to view a list of medication options. prednisone, hydroxyzine, diclofenac, loratadine, fluticasone nasal, cetirizine, triamcinolone, promethazine, dexamethasone, celecoxib. Cyproheptadine is in a class of drugs called antihistamines. It works by blocking the action of histamine in the body. The U.S. Food and Drug.